P=N/A, N=1000, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

The ex vivo skin permeation study signifies that the NTB-loaded LPS gel improved the permeation and retention of NTB by 3.1- and 2.6-fold, respectively, compared to the plain NTB-loaded gel. Collectively, these findings highlight the potential of NTB-loaded liposomal gel as an effective, noninvasive, and patient-friendly approach for melanoma management.

This first reported case of SM-AML with KIT p.Asp419del highlights the need for comprehensive molecular testing and tailored therapy in atypical presentations.

P1/2, N=50, Not yet recruiting, Friedrich-Schiller-Universitaet Jena

Cellular Ki values of dasatinib and imatinib for 25 kinases by FPCBA were broadly concordant with kinobead LC/MS measurements in cancer cell lysates but diverged substantially from recombinant KINOMEscan values, with divergences attributable to competition with ATP, autoinhibition, and membrane-dependent conformational states in living cells. FPCBA enables profiling of native protein-small molecule interactions in a physiologically relevant cellular context.

This case highlights the integration of pathological features, c-kit exon 11 mutation status, and imaging findings in the diagnosis and management of high-risk GSTs. The 4-year recurrence-free survival confirms the effectiveness of risk-stratified adjuvant therapy with imatinib.

The patient was treated with cytoreductive therapy, followed by imatinib, with a favorable clinical and hematologic response. This case highlights the potential for massive splenomegaly to mask CML and emphasizes the importance of early molecular testing. Splenectomy may unmask underlying hematologic malignancy through significant postoperative hematologic changes.

P1/2, N=14, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting

Vodobatinib demonstrates a favorable preclinical absorption, distribution, metabolism, and excretion profile, with high metabolic stability, minimal efflux liability, and selective tissue distribution. These findings support its continued clinical development in chronic myeloid leukemia and potentially other Bcr-Abl 1 driven malignancies.

P1, N=30, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting

Zingerone alone or in combination with nilotinib also reduced phosphorylation of PI3K, AKT, and mTOR in resistant cells. Zingerone enhances the inhibitory effects of nilotinib on CML cell survival and overcomes nilotinib resistance by suppressing the PI3K pathway.

This study analyzed 5-year follow-up data and immune profiling from two independent phase 2 trials, JALSG N-STOP216 (nilotinib [NIL], n=51) and D-STOP216 (dasatinib [DAS], n=49), involving patients who discontinued frontline 2G-TKIs after sustaining deep molecular response (DMR) for ≥2 years. These findings suggest that 2G-TKI-specific off-target effects influence TFR sustainability by modulating the immune microenvironment and the CD4+ helper cell status. JALSG N-STOP216 (UMIN000024984); JALSG D-STOP216 (UMIN000024985).